New vaccine for necrotic enteritis in broilers launched
By Canadian Poultry magazineNews Company News
New Huvepharma vaccine shown to be effective against NE due to Clostridium perfringens type A in chickens.
Huvepharma Canada Corporation Inc. has launched a new vaccine that has been shown to be effective against necrotic enteritis (NE) due to Clostridium perfringens type A in broiler chickens.
“Clostridium Perfringens Type A vaccine is the first live vaccine in Canada that can be mass administered to broiler chickens at day of age or older for necrotic enteritis (NE),” says Chris Wilson, general manager of Huvepharma Canada Corporation Inc.
Clostridium Perfringens Type A vaccine utilizes the proprietary and unique recombinant attenuated salmonella vaccine (RASV) technology from Curtiss Healthcare, Inc. as the delivery platform to elicit an optimal immune response to protect chickens from NE.
The RASV platform applies advanced enabling recombinant technology to modify salmonella to serve as a vector to help protect against NE whilst ensuring safety to the user, animal and environment.
Dr. Kirsten De Keyser, technical service, Huvepharma Canada Corporation Inc., adds, “Necrotic enteritis prevention and control has become increasingly important for the performance, health and welfare of our broilers. It’s through this exciting innovation that we help our customers combat this disease for the first time using vaccination.”
Print this page